Of course, self-perception of one's relational value is sometimes inaccurate, and a good deal of research has examined instances in which people underestimate or overestimate their relational value in other people's eyes. Importantly, like other systems that monitor the environment for threats, the sociometer seems to be biased in the direction of false positives. This bias reflects a functional feature of the system, decreasing the likelihood that people will miss cues that their relational value is low or declining. However, the downside is that this bias generates unnecessary distress and sometimes leads people to overreact to relatively benign signs that others do not value their relationship as much as they desire.
The Desire in hindi
Download Zip: https://7cepchistilo.blogspot.com/?download=2vKjrp
According to General Assembly resolution A/RES/61/271 of 15 June 2007, which established the commemoration, the International Day is an occasion to "disseminate the message of non-violence, including through education and public awareness". The resolution reaffirms "the universal relevance of the principle of non-violence" and the desire "to secure a culture of peace, tolerance, understanding and non-violence".
Happiness is more than a good feeling or a yellow smiley face. It's the feeling of truly enjoying your life, and the desire to make the very best of it. Happiness is the "secret sauce" that can help us be and do our best.
Layout table for study information Study Type : Interventional (Clinical Trial) ActualEnrollment : 230 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant, Investigator) Primary Purpose: Supportive Care Official Title: Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women With Breast or Gynecologic Cancer Actual Study Start Date : May 31, 2017 Actual Primary Completion Date : February 22, 2021 Actual Study Completion Date : February 22, 2021 Resource links provided by the National Library of Medicine Drug Information available for: Bupropion hydrochloride Bupropion Genetic and Rare Diseases Information Center resources: Ovarian Cancer Ovarian Epithelial Cancer Vaginal Cancer Vulvar Cancer U.S. FDA Resources Arms and Interventions Go to Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information Arm Intervention/treatment Experimental: Bupropion 150 mgOne Bupropion 150 mg XL capsule by mouth (PO) in a.m. daily for one week; one Bupropion 150 mg XL capsule and one placebo capsule daily for 8 weeks; one placebo capsule daily for one 1 week (titration off). Drug: Bupropion 150 mg XLBy mouthOther Names:Amfebutamone
BUPROPION HYDROCHLORIDE
BW 323U66
Forfivo XL
Wellbutrin
Zyban
Drug: PlaceboBy mouth Experimental: Bupropion 300 mgOne Bupropion 150 mg XL capsule PO in a.m. daily for one week; two Bupropion 150 mg XL capsules PO in a.m. daily for 8 weeks (300 mg target dose); one Bupropion 150 mg XL capsule PO in a.m. daily for 1 week (titration off) Drug: Bupropion 150 mg XLBy mouthOther Names:Amfebutamone
BUPROPION HYDROCHLORIDE
BW 323U66
Forfivo XL
Wellbutrin
Zyban
Placebo Comparator: PlaceboOne placebo capsule PO in a.m. daily for 1 week; two placebo capsules PO in a.m. daily for 8 weeks; one placebo capsule PO in a.m. daily for 1 week (titration off) Drug: PlaceboBy mouth Outcome Measures Go to Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information Primary Outcome Measures : Change From Baseline at 9 Weeks in the Desire Subscore of the Female Sexual Function Index ("Sexual Desire") [ Time Frame: Baseline (prior to randomization) and 9 weeks from start of study treatment (within 21 days of randomization) ]The desire subscore of the female sexual function index (FSFI) measures self-reported sexual desire. Possible scores range from 1.2 to 6, with higher scores indicating increased desire. Change score is calculated by subtracting baseline from later score, with a positive change score indicating increased desire. This measure is referred to as "sexual desire" in the protocol. Secondary Outcome Measures : Change From Baseline in the Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Score [ Time Frame: Baseline (prior to randomization) and 5 and 9 weeks from start of study treatment (within 21 days of randomization) ]The PROMIS fatigue score measures self-reported fatigue symptoms over the past 7 days. Possible scores range from 33.1 to 77.8, with higher scores indicating more fatigue. Change score is calculated by subtracting baseline from later score, with a positive change score indicating increased fatigue. Change From Baseline at 5 Weeks in Desire Subscore of the FSFI ("Sexual Desire") [ Time Frame: Baseline (prior to randomization) and 5 weeks from start of study treatment (within 21 days of randomization) ]The desire subscore of the female sexual function index (FSFI) measures self-reported sexual desire. Possible scores range from 1.2 to 6, with higher scores indicating increased desire. Change score is calculated by subtracting baseline from later score, with a positive change score indicating increased desire. This measure is referred to as "sexual desire" in the protocol. Change From Baseline in the PROMIS Global Satisfaction With Sex Life Subscore of Sexual Function and Satisfaction Measure ("Sexual Desire and Satisfaction") [ Time Frame: Baseline (prior to randomization) and 5 and 9 weeks from start of study treatment (within 21 days of randomization) ]The PROMIS Global Satisfaction with Sex Life subscore measures self-reported global satisfaction, interest, and interference in sexual health over the past 7 days. Possible scores range from 3 to 30, with higher scores indicating more satisfaction with sex life. Change score is calculated by subtracting baseline from later score, with a positive change score indicating increased satisfaction. This score is referred to as the "PROMIS sexual desire and satisfaction measure" in the protocol. Change From Baseline in FSFI Total Score ("Sexual Functioning") [ Time Frame: Baseline (prior to randomization) and 5 and 9 weeks from start of treatment (within 21 days of randomization) ]The FSFI total score measures self-reported female sexual functioning covering the major domains arousal, satisfaction, and orgasm, and including lubrication and pain. Possible scores range from 2 to 36, with higher scores indicating better functioning. Change score is calculated by subtracting baseline from later score, with a positive change score indicating increased functioning. This measure is referred to as "sexual functioning" in the protocol. Change From Baseline in the Patient Health Questionnaire (PHQ)-4 Score ("Depressive Mood") [ Time Frame: Baseline (prior to randomization) and 5 and 9 weeks from start of treatment (within 21 days of randomization) ]The PHQ-4 is a brief screening questionnaire for depression. Possible scores range from 0 to 12, with higher scores indicating more severe depression. Change score is calculated by subtracting baseline from later score, with a negative change score indicating decreased severity of depression. This measure is referred to as "depressive mood" in the protocol. Global Impression of Change at 9 Weeks ("Perception of Change") [ Time Frame: 9 weeks from start of study treatment (within 21 days of randomization) ]Participants are asked, "Since beginning the study agent, my desire of sexual intimacy is:" with seven possible answers of "very much better," "moderately better," "a little better," "about the same," "a little worse," "moderately worse," and "very much worse." The first three answers have been categorized as "Better' and the last three answers as "Not Better". This measure is referred to as "perception of change" in the protocol. Perception of Risk vs. Benefit at 9 Weeks [ Time Frame: 9 weeks from start of study treatment (within 21 days of randomization) ]Participants are asked, "Were the benefits of this treatment greater than any side effects?" Number of Participants With a Grade 3 or Higher Adverse Event Over the Course of the Study [ Time Frame: Adverse events were evaluated 1,2,5,7, and 9 weeks from start of study treatment (within 21 days of randomization). ]Common Terminology Criteria for Adverse Events (version 4) grades adverse event severity from 1=mild to 5=death. Summary data is provided in this outcome measure.; see Adverse Events Module for specific adverse event data. Number of Participants With Most Severe Response for Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) at 9 Weeks [ Time Frame: 9 weeks from start of study treatment (within 21 days of randomization). ]Questions refer to the participants' experiences for the past 7 days of a given symptom in terms of frequency (never, rarely, occasionally, frequently, almost constantly), severity (none, mild, moderate, severe, very severe), interference with usual or daily activities (not at all, a little bit, somewhat, quite a bit, very much). Eligibility CriteriaGo to Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: Female Accepts Healthy Volunteers: No Criteria Inclusion Criteria:
2ff7e9595c